Landscape Capital Management’s Axsome Therapeutics AXSM Stock Holding History

Landscape Capital Management’s Portfolio AXSM Stock Details AXSM Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	–	Sell	-14,129	Closed	-$2.39M	–	660
2026 Q1	$2.39M	Sell	14,129 -1,176	-8%	-$203K	0.15%	210
2025 Q4	$2.8M	Sell	15,305 -3,983	-21%	-$556K	0.19%	167
2025 Q3	$2.34M	Buy	19,288 +13,579	+238%	+$1.53M	0.15%	207
2025 Q2	$596K	Buy	5,709 +292	+5%	+$30.9K	0.05%	425
2025 Q1	$632K	Buy	+5,417	New	+$617K	0.06%	377
2024 Q4	–	Sell	-6,513	Closed	-$585K	–	723
2024 Q3	$585K	Buy	+6,513	New	+$569K	0.06%	373

Other funds holding AXSM

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM

Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

Invesco Atlanta, Georgia $1.26T AUM 61.52% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

DTC

Deep Track Capital Greenwich, Connecticut $6.87B AUM 205.24% 1-Year Est. Return

Two Sigma Investments New York $138B AUM 41.87% 1-Year Est. Return

Landscape Capital Management's AXSM Position: Q2 2026 in Review

Landscape Capital Management sold out of Axsome Therapeutics (AXSM) in Q2 2026, closing a stake of 14,129 shares — an estimated $2.39M sold.

Landscape Capital Management first reported a position in AXSM in Q3 2024 and held it in 6 quarters. The position peaked at $2.8M in Q4 2025. 506 funds tracked by Wall St. Rank hold AXSM as of Q2 2026.

Landscape Capital Management reported no remaining Axsome Therapeutics position as of Q2 2026 after selling out during the quarter.
Landscape Capital Management sold 14,129 Axsome Therapeutics shares in Q2 2026, an estimated $2.39M.
Landscape Capital Management first reported a position in Axsome Therapeutics in Q3 2024 and held it in 6 quarters.
Landscape Capital Management's Axsome Therapeutics position peaked at $2.8M in Q4 2025.
506 funds tracked by Wall St. Rank held Axsome Therapeutics as of Q2 2026.

Based on Landscape Capital Management's 13F filing for Q2 2026, filed 12 Aug 2026.